Akesis Gemini360™ Clinical Value
Innovating radiation medicine
As a pioneer in developing the world-first multi-modality RT platform, Akesis brought “X/γ Integrated Radiation Therapy System”(Gemini360) by integrating 1) a 6MV 40cm x 40cm slip-ring based LINAC workhorse and 2) a whole-body rotational Gamma system for SRS/SBRT. Both treatment modalities are enhanced with end-to-end imaging guidance and intelligent adaptive therapy capabilities. It is FDA 510k pending (510k clearance is expected in 2024 Q1).
Gemini360 holds unique value for multi-targets simultaneous irradiation, i.e., Spatially Fractionated Radiation Therapy (SFRT). Preliminary clinical studies have demonstrated significant advantages in the clinical scenario of primary tumors with nearby or distant metastases, as shown in case (1) with lymph node metastasis in the neck and chest and metastases in the lungs. Furthermore, Gemini360 exhibits notable advantages in local dose painting, addressing local advanced tumors’ hypoxic zones, local dose escalation, and simultaneous preventive irradiation outside the target area, as illustrated in case (2) liver cancer and (3) lung cancer brain metastasis. Additionally, Gemini360 could facilitate grid/lattice irradiation for late-stage/giant tumors with suboptimal responses to conventional therapy. We are calling for wide collaborations with clinical centers for ongoing cutting-edge clinical research exploring the full benefit to cancer patients.
Case 1
After left breast cancer surgery, Metastasis in neck and mediastinal lymph nodes, plus lung oligometastasis.
